Page contents Key factsDecisionRelated medicine informationKey facts Invented name GalvusGalvus Active Substance vildagliptin Therapeutic area Endocrinology-Gynaecology-Fertility-Metabolism Decision number P/177/2011 PIP number EMEA-000700-PIP02-10 Pharmaceutical form(s) Tablet Condition(s) / indication(s) Treatment of type II diabetes mellitus Route(s) of administration Oral use Contact for public enquiries Novartis Europharm LimitedSwitzerlandpaediatric.enquiries@novartis.comPhone: +41 61 324 1111Fax: +41 61 324 8001 Decision type W: decision granting a waiver in all age groups for all conditions or indications Decision date 26/08/2011DecisionP/177/2011: EMA decision of 26 August 2011 on the granting of a product specific waiver for vildagliptin (Galvus), (EMEA-000700-PIP02-10)AdoptedReference Number: EMA/691227/2011 English (EN) (72.76 KB - PDF)First published: 03/10/2011Last updated: 03/10/2011ViewRelated medicine informationGalvusShare this page